The study’s novel discovery is that VIRMA regulates the expression of UBR5 via m6A-mediated mechanism, ultimately leading to the progression of HNSCC, suggesting that VIRMA has shown potential as a biomarker for the prognosis of HNSCC. Here, UBR5 is linked to head and neck squamous cell carcinoma.